Trials / Unknown
UnknownNCT02646137
Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma
Comparison of Single Session Transarterial Chemoembolization Combined With Microwave Ablation or Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for patients with surgically unresectable hepatocellular carcinoma.
Detailed description
To compare between combination treatment with radiofrequency or microwave ablation followed by transarterial chemoembolization and performed in a single session.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Transarterial chemoembolization (TACE) | TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles |
| PROCEDURE | Radiofrequency ablation combined with TACE | Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition |
| PROCEDURE | Microwave ablation combined with TACE | Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis |
Timeline
- Start date
- 2015-01-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2016-01-05
- Last updated
- 2018-01-09
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT02646137. Inclusion in this directory is not an endorsement.